Abubakr Bajwa, MD
Pulmonary Disease · Jacksonville, FLNPI 1467442392
Payments from drug & device makers
Across 650 payments — averaging $2187.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$830K
- AstraZeneca$155K
- Boehringer Ingelheim$109K
- Janssen Research & Development, LLC$81K
- Intuitive Surgical$65K
- Actelion Pharmaceuticals, Ltd$52K
- plus $131K from 23 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 267 | $829,530 |
| AstraZeneca | 34 | $154,564 |
| Boehringer Ingelheim | 80 | $108,889 |
| Janssen Research & Development, LLC | 9 | $80,984 |
| Intuitive Surgical | 76 | $65,207 |
| Actelion Pharmaceuticals, Ltd | 15 | $51,920 |
| Actelion Pharmaceuticals US, Inc. | 65 | $50,963 |
| Insmed, Inc. | 33 | $42,529 |
| Bayer | 13 | $29,167 |
| Acerta Pharma LLC | 1 | $4,472 |
| Pulmonx Corporation | 12 | $1,915 |
| Merck | 8 | $426 |
| Inspire Medical Systems, Inc. | 7 | $369 |
| GSK | 7 | $221 |
| Genentech USA, Inc. | 5 | $161 |
| Vapotherm Inc | 1 | $123 |
| Ambu Inc. | 1 | $80 |
| Mylan Specialty L.p. | 2 | $39 |
| Mallinckrodt Enterprises LLC | 2 | $37 |
| Gilead | 2 | $29 |
| Sunovion Pharmaceuticals Inc. | 2 | $28 |
| Johnson & Johnson | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $20 |
| Grifols USA, LLC | 1 | $19 |
| Sanofi | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| AbbVie | 1 | $14 |
| Novartis | 1 | $11 |
How this compares
$1,421,792 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Jacksonville
- Charles BurgerJacksonville$5.6M
- Jennifer FultonJacksonville$791K
- Sebastian Fernandez-BussyJacksonville$559K
- Remzi BagJacksonville$556K
- Jose Soto SotoJacksonville$549K
- Augustine LeeJacksonville$533K
- Jorge MalleaJacksonville$478K
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.